Immunohistochemical expression of glucose transporter Glutl and cyclin D 1 in breast carcinomas with negatine lymph nodes

All malignant cells appear to have increased needs for glucose in vitro as well as in vivo. The enhanced glucose uptake is mediated through transporters (Gluts), whose action and expression are regulated by oncogenes and growth factors. Cyclin D1 is a nuclear protein that plays an important role in regulating the cell cycle by promoting entry of cells from the G1 to S phase. Increased expression of Glut1 glucose transporter and cyclin D1 have been reported in several neoplasms. In the present study we examined the expression of Glut1 and cyclin D1 in breast carcinomas with negative lymph nodes. We studied 78 infiltrating ductal carcinomas (25 grade 1, 36 grade 2, and 17 grade 3) with negative lymph nodes. Glut1 was expressed in 28% of grade 1, 63.8% of grade 2 and 58.7% of grade 3 carcinomas. Nuclear expression of cyclin D1 was detected in 32% of grade 1, 44.4% of grade 2, and 41.2% of grade 3 carcinomas. From our study it appears that in breast carcinomas with negative lymph nodes Glut1 expression is better correlated to the grade of the neoplasm than cyclin D1.

Glucose transporter; Cyclin Dl; Breast cancer

[1] Flier J.S., Mueckler M.M., Usher P., Lodish H.F.: "Elevated levels of glucose transport and transporter messanger RNA are induced by ras or src oncogenes". Science, 1987, 235, 1492.

[2] Hiraki Y., Rosen O.M., Birnbaum M.J.: "Growth factors rapidly induce expression of the glucose transporter gene". J. Biol. Chem., 1988, 263, 13655.

[3] Mcrrall N.W., Plevin R., Gould G.W.: "Growth factors, mitogens, oncogenes and the regulation of glucose transport". Cell. Sign., 1993, 5. 667.

[4] Mueckler M.: "Facilitative glucose transporters". Eur. J. Biochem. 1994, 219, 713.

[5] Pessin J.E., Bell G.I.: "Mammalian facilitating glucose transporter family:structure and molecular regulation". Annu. Rev. Physiol., 1992,54, 911.

[6] Maher F., Yannucci S.J., Simpson I.A.: "Glucose transporter proteins in brain". FASEB J., 1994, 8 (13), 1003.

[7] Camps S., Vilaro S., Testar X., Palacin M., Zorzano A.: "High and polarized expression of GLUT l glucose trasporters in epithelial cells from mammary gland: acute downregulation of GLUT1 carriers by weaning". Endocrinology, 1994, 134, 924.

[8] Jansson T., Wennergren M., Illsley N.P.: "Glucose trasporter protein expression in human placenta throughout gestation and in intrauterine growth retardation". J. Clin. Endocrinol. Metab., 1993, 77, 1554.

[9] Guerin C., Laterra J., Drewes L.R., Brem H., Goldstein G.: "Vascular expression of glucose trasporter in experimental brain neoplasms". Am. J. Pathol., 1992, 140, 417.

[10] Younes M., Lechago L.V., Somoano J.R., Morcharaf M., Lechago J.: "Wide expression of the human erythrocyte glucose transporter Glutl in benign and malignant human tissues". Cancer Res., 1996, 56, 1164.

[11] Mellanen P., Minn H., Grenman R., Harkonen P.: "Expression of glucose transporters in head-and-neck tumors". Int. J. Cance,; 1994, 56, 622.

[12] Haber R.S., Weiser K.R., Pritzker A., Reder I., Burstein D.E.； "Glutl glucose transporter expression in benign and malignant thyroid nodules". Thyroid., 1997, 7, 363.

[13] Nagase Y., Takata K., Moriyama N., Aso Y., Murakami T., Hirano H.: "Immunohistochemical localization of glucose transporters in human renal carcinoma". J. Urol., 1995, 153, 798.

[14] Younes M., Brown R.W., Stephenson M., Gondo M., Cagle P.: "Overexpression of Glut I and Glut3 in Stage I nonsmall cell lung carcinoma is associated with poor survival". Cancer, 1997, 80, 1046.

[15] Younes M., Brown R.W., Mody D.R., Fernandez L., Laucirica R.: "Glut I expression in human breast carcinoma: correlation with known prognostic markers". Anticancer Res., 1995, 15, 2895.

[ 16] Burstein D.E., Reder I., Weiser K., Tong T., Protsker A., Haber R.S.； "Glut! glucose transporter: A highly sensitive marker of malignancy in body cavity effusions". Mod. Pathol., 1998, 11, 392.

[17] Sherr C.J.: "GI phase progression: cyclin on cue". Cell., 1994, 79, 551.

[18] Morgan D.O.: "Principles of cdk regulation". Nature, 1995,3 71, 131.

[19] Hengst L., Dulic V., Slingerland J.M., Lees E., Reed S.I.: "A cellcycle regulated inhibitor of cyclin-dependent kinases". PNAS, 1994, 91, 5291.

[20] Reed S.l., Bailly E., Dulic V., Hengst L., Resnitzky D., Slingerland J.: "GI control in mammalian cells". J. Cell. Sci., 1994, 18, 69.

[21] Murray A.W.: "Creative blocks: cell-cycle checkpoints and feedback controls". Nature, 1992, 359, 599.

[22] Zwijsen R.M.L.. Klompmarker R., Wientjens E., Kristel P., van der Burg B., Michalidis R.: "Cyclin DI triggers autonomous growth of breast cancer cells by governing cell cycle exit". Mol Cel. Biol., 1996, 16, 2554.

[23] Xiong Y., Menninger J., Beach D., Ward D.C.: "Molecular cloning and chromosomal mapping of CCND genes encoding human Dtype cyclins". Genomics, 1992, 13, 574.

[24] Lin B.,B rynes R.K.,G elb A.B.,M cCourty A.,A min M.,M edeiros J.: "Cyclin DI expression in renal cell carcinomas and oncocytomas: An immunohistochernical study". Mod. Pathol., 1988, 11. 1075.

[25] Bartkova J., Lukas J., Strauss M., Bartek J.: "Cyclin D1 oncoprotein abberantly accumulates in malignancies of diverse histogenesis". Oncogene, 1995, 10, 775.

[26] Bartkova J., Lukas J., Muller J., Lutzhoft D., Strauss M., Bartek J.: "Cyclin D1 protein expression and function in human breast cancer". Int. J. Cancer, 1994, 57, 353.

[27] Zhang S.Y., Caamano J., Cooper F., Guo X., Klein-Szanto A.: "Irnmunohistochemistry of cyclin DI in human breast cancer". Am. J. Clin. Pathol., 1994, 102, 695.

[28] Zhu X.L., Hartwick W., Rohan T., Kandel R.: "Cyclin Dl gene amplification and protein expression in benign breast disease and breast carcinoma". Mod. Pathol., 1998, 11, 1082.